PMID- 34455476
OWN - NLM
STAT- MEDLINE
DCOM- 20220324
LR  - 20220324
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 269
IP  - 4
DP  - 2022 Apr
TI  - Clinical difference after the first optic neuritis between 
      aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated 
      disorders.
PG  - 1996-2003
LID - 10.1007/s00415-021-10764-7 [doi]
AB  - OBJECTIVE: To investigate the difference in clinical course after the first optic 
      neuritis (ON) between aquaporin-4 IgG-associated disorder (AQPAD) and myelin 
      oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD) METHODS: In this 
      study, 31 eyes in 24 patients with AQPAD and 26 eyes in 18 patients with MOGAD 
      were included. The clinical course for the first 6 months after the first ON was 
      monitored by a retrospective cohort study. Best-corrected visual acuity (BCVA) 
      was observed before the onset and at nadir, 2 weeks (2 W), 1 month (1 M), 
      2 months (2 M), 3 months (3 M) and 6 months (6 M). The decimal BCVA was converted 
      to the logarithm of the minimal angle of resolution (logMAR) for statistical 
      analyses. RESULTS: MOGAD eyes showed longer median number of days from ON onset 
      to nadir (6.0 vs. 11.5, P = 0.012) and to treatment (7.0 vs. 11.0, P = 0.020) 
      than AQPAD eyes. The median logMAR was higher in AQPAD eyes than in MOGAD eyes at 
      nadir (2.00 vs. 1.77, P = 0.050), 2 W (1.85 vs. 0.40, P = 0.001), 2 M (0.023 vs. 
      - 0.079, P = 0.032) and 3 M (0.046 vs. - 0.079, P = 0.002). The median time to 
      recovery of BCVA to 0.7 was longer in AQPAD eyes than in MOGAD eyes (44.0 vs. 
      21.0 days, P = 0.024), but that to BCVA 1.0 was not different between the two 
      disorders (168.0 vs. 40.0 days, respectively, P = 0.056). CONCLUSION: Compared 
      with MOGAD eyes, AQPAD eyes tended to show worse visual outcome even during the 
      first ON episode.
CI  - (c) 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
FAU - Masuda, Hiroki
AU  - Masuda H
AUID- ORCID: 0000-0002-4106-6482
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan. hiroki_masuda@chiba-u.jp.
FAU - Mori, Masahiro
AU  - Mori M
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
FAU - Yokouchi, Hirotaka
AU  - Yokouchi H
AD  - Department of Ophthalmology and Visual Science, Graduate School of Medicine, 
      Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
FAU - Uzawa, Akiyuki
AU  - Uzawa A
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
FAU - Uchida, Tomohiko
AU  - Uchida T
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
FAU - Muto, Mayumi
AU  - Muto M
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
AD  - Department of Neurology, Chiba Rosai Hospital, 2-16, Tatsumidai-higashi, 
      Ichihara, 290-0003, Japan.
FAU - Ohtani, Ryohei
AU  - Ohtani R
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
AD  - Department of Neurology, JR Tokyo General Hospital, 2-1-3, Yoyogi, Shibuya-ku, 
      Tokyo, 151-8528, Japan.
FAU - Aoki, Reiji
AU  - Aoki R
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
FAU - Yamamoto, Shuichi
AU  - Yamamoto S
AD  - Department of Ophthalmology and Visual Science, Graduate School of Medicine, 
      Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan.
FAU - Kuwabara, Satoshi
AU  - Kuwabara S
AD  - Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, 
      Inohana, Chuo-ku, Chiba, 260-8670, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210829
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Aquaporin 4)
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
SB  - IM
MH  - Aquaporin 4
MH  - Autoantibodies
MH  - Humans
MH  - Immunoglobulin G
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - *Neuromyelitis Optica/complications
MH  - *Optic Neuritis/complications
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Aquaporin-4
OT  - Myelin oligodendrocyte glycoprotein
OT  - Neuromyelitis optica spectrum disorder
OT  - Optic neuritis
OT  - Visual acuity
EDAT- 2021/08/30 06:00
MHDA- 2022/03/25 06:00
CRDT- 2021/08/29 21:05
PHST- 2021/06/16 00:00 [received]
PHST- 2021/08/18 00:00 [accepted]
PHST- 2021/08/17 00:00 [revised]
PHST- 2021/08/30 06:00 [pubmed]
PHST- 2022/03/25 06:00 [medline]
PHST- 2021/08/29 21:05 [entrez]
AID - 10.1007/s00415-021-10764-7 [pii]
AID - 10.1007/s00415-021-10764-7 [doi]
PST - ppublish
SO  - J Neurol. 2022 Apr;269(4):1996-2003. doi: 10.1007/s00415-021-10764-7. Epub 2021 
      Aug 29.